Cost-effectiveness of Outpatient Management for Febrile Neutropenia in Children With Cancer
- 1 February 2011
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 127 (2) , e279-e286
Abstract
OBJECTIVE: Inpatient management remains the standard of care for treatment of febrile neutropenia (FN) in children with cancer. Clinical data suggest, however, that outpatient management might be a safe and efficacious alternative for patients with low-risk FN episodes.METHODS: A cost-utility model was created to compare 4 treatment strategies for low-risk FN. The base case considered pediatric cancer patients with low-risk FN. The model used a health care payer's perspective and a time horizon of 1 FN episode. Four treatment strategies were evaluated: (1) entire treatment in hospital with intravenous antibiotics (HospIV); (2) early discharge consisting of 48 hours of inpatient observation with intravenous antibiotics followed by oral outpatient treatment (EarlyDC); (3) entirely outpatient management with intravenous antibiotics (HomeIV); and (4) entirely outpatient management with oral antibiotics (HomePO). Outcome measures were quality-adjusted FN episodes (QAFNEs), costs (Canadian dollars), and incremental cost-effectiveness ratios. Parameter uncertainty was assessed with probabilistic sensitivity analyses.RESULTS: The most cost-effective strategy was HomeIV. It was cost-saving ($2732 vs $2757) and more effective (0.66 vs 0.55 QAFNE) as compared with HomePO. EarlyDC was slightly more effective (0.68 QAFNE) but significantly more expensive ($5579) than HomeIV, which resulted in an unacceptably high incremental cost-effectiveness ratio of more than $130 000 per QAFNE. HospIV was the least cost-effective strategy because it was more expensive ($14 493) and less effective (0.65 QAFNE) than EarlyDC.CONCLUSION: The findings of this decision-analytic model indicate that the substantially higher costs of inpatient management cannot be justified on the basis of safety and efficacy considerations or patient/parent preferences.Keywords
This publication has 33 references indexed in Scilit:
- Randomized Control Trial Comparing Oral Amoxicillin-clavulanate and Ofloxacin With Intravenous Ceftriaxone and Amikacin as Outpatient Therapy in Pediatric Low-risk Febrile NeutropeniaJournal of Pediatric Hematology/Oncology, 2009
- Healthcare-associated infections in pediatric cancer patients: results of a prospective surveillance study from university hospitals in Germany and SwitzerlandBMC Infectious Diseases, 2008
- Variation in policies for the management of febrile neutropenia in United Kingdom Children's Cancer Study Group centresArchives of Disease in Childhood, 2007
- Medical and non‐medical barriers to outpatient treatment of fever and neutropenia in children with cancerPediatric Blood & Cancer, 2007
- Information Created to Evade Reality (ICER)PharmacoEconomics, 2006
- Prospective audit of treatment of paediatric febrile neutropenia in AustralasiaJournal of Paediatrics and Child Health, 2005
- Outpatient, sequential, parenteral‐oral antibiotic therapy for lower risk febrile neutropenia in children with malignant diseaseCancer, 2003
- Visual Analog Scales: Do They Have a Role in the Measurement of Preferences for Health States?Medical Decision Making, 2001
- Visual Analog Scales: Do They Have a Role in the Measurement of Preferences for Health States?Medical Decision Making, 2001
- Utility approach to measuring health-related quality of lifeJournal of Chronic Diseases, 1987